Padagis US LLC Initiates Class III Recall of Triamcinolone Acetonide Cream Due to Potency Deviations
Padagis US LLC has completed a Class III recall (D-0048-2025) of 10,872 jars of Triamcinolone Acetonide Cream USP, 0.025%, due to subpotent and superpotent drug findings. This voluntary action, initiated October 11, 2024, stemmed from out-of-specification stability test results at their Minneapolis, MN facility. Procurement and regulatory teams must scrutinize supplier quality systems, particularly for long-term stability and container uniformity, to mitigate supply chain risks.
FDA Class III Recall: Padagis US LLC's Triamcinolone Acetonide Cream Potency Issues
Padagis US LLC, operating from its Minneapolis, MN facility at 3940 Quebec Ave N, has concluded a Class III voluntary recall, identified as D-0048-2025, for its Triamcinolone Acetonide Cream USP, 0.025%. The recall, initiated on October 11, 2024, and terminated on September 29, 2025, involved 10,872 jars distributed nationwide across the USA. The critical issue identified was that the drug product was found to be both subpotent and superpotent. This significant deviation from quality specifications was discovered through out-of-specification (OOS) assay results recorded during long-term stability testing, specifically as part of the Uniformity of Container test. For procurement directors, this event underscores the imperative of stringent quality assurance protocols from suppliers. A terminated recall indicates that the firm has completed all necessary actions, but the underlying quality system failure remains a critical data point for future supplier evaluations. Business development executives should note that such potency variations can severely impact product efficacy and patient safety, eroding trust in the brand and potentially leading to market withdrawal if not addressed proactively.
Supply Chain Vulnerability: Impact of Potency Deviations on Downstream Manufacturers
The recall of 10,872 jars of Triamcinolone Acetonide Cream USP, 0.025%, by Padagis US LLC, despite being a Class III recall, presents tangible risks for downstream manufacturers, distributors, and healthcare providers. For supply chain VPs, the nationwide distribution pattern of the affected lots (2024154238, 2024174344) means a broad market exposure and potential disruption. Although the recall is terminated, the initial event would have necessitated immediate inventory checks, quarantine, and return procedures, incurring significant logistical costs and administrative burdens. Procurement directors must recognize that even a Class III recall, which typically indicates a low probability of serious adverse health consequences, still signifies a fundamental breakdown in manufacturing quality control. This necessitates a re-evaluation of supplier qualification processes, particularly for generic topical corticosteroids like Triamcinolone Acetonide, where consistent potency is crucial for therapeutic outcomes. The incident highlights the need for robust quality agreements that mandate transparent reporting of all OOS events and stability data, ensuring that product integrity is maintained throughout its shelf life.
Broader Regulatory Landscape: Persistent Quality Control Challenges Across Pharma
This Padagis US LLC recall of Triamcinolone Acetonide Cream fits into a broader pattern of regulatory scrutiny by the FDA concerning manufacturing quality and supply chain integrity within the pharmaceutical industry. Regulatory affairs heads should view this event not in isolation, but as part of an ongoing trend where the FDA is rigorously enforcing Current Good Manufacturing Practices (CGMP). Recent parallel events, such as Pfizer's Class I recalls for Bleomycin Injection and Sodium Bicarbonate Injection due to glass particulate matter, or Sandoz's and Teva's Class II recalls linked to temperature excursion risks, underscore a pervasive challenge across diverse therapeutic areas and product types. While the specific issues vary—from particulate matter and temperature deviations to potency variations in Padagis's case—the common denominator is a failure in quality management systems. This consistent regulatory pressure means that all pharmaceutical companies, regardless of their market position, must prioritize comprehensive quality control, from raw material sourcing to finished product stability, to avoid costly recalls and maintain market access.
Proactive Risk Management: Strengthening Supplier Oversight for Pharmaceutical Ingredients
For procurement directors and supply chain VPs, the Padagis US LLC recall serves as a critical reminder of the necessity for proactive risk management in supplier relationships. Relying solely on a supplier's self-declaration of compliance is insufficient. Companies must implement rigorous supplier qualification programs that include regular audits, focusing specifically on areas like stability testing protocols and uniformity of container validation. The detection of subpotent and superpotent drug product during long-term stability testing indicates a potential systemic issue that could affect other products from the same manufacturing site. Regulatory affairs heads should ensure that supplier quality agreements are comprehensive, detailing expectations for stability data, change control, and immediate notification of any out-of-specification results. Investing in robust supplier monitoring and diversification strategies is paramount to mitigate the impact of such recalls, safeguarding product availability, and protecting patient safety. This proactive approach minimizes the risk of supply disruptions and avoids the significant financial and reputational costs associated with product quality failures.
Quality Assurance Imperatives: The Role of Stability Testing and Container Uniformity
The specific reason for the Padagis US LLC recall—out-of-specification assay results during uniformity of container testing as part of long-term stability studies—highlights fundamental quality assurance imperatives. For regulatory affairs and quality control teams, this points to the critical importance of these tests in ensuring drug product integrity throughout its shelf life. Uniformity of container testing verifies that the active pharmaceutical ingredient (API) is evenly distributed within each individual container, which is vital for consistent dosing. Long-term stability testing, on the other hand, assesses how the quality of a drug product varies with time under the influence of environmental factors like temperature and humidity. Failures in these areas, leading to subpotency or superpotency, mean that patients may not receive the intended therapeutic effect or could experience adverse reactions. Business development executives must understand that such quality lapses, even for a Class III recall, can undermine market confidence and create barriers to future product launches. Robust investment in analytical capabilities and adherence to cGMPs for stability programs are non-negotiable for maintaining product quality and regulatory compliance.